senolytic therapies for age-related diseases and disorders
Rockfish Bio’s stated belief barely moves across these two snapshots. In December 2021, the company framed itself around senolytic therapies for age related diseases and disorders. In January 2022, it said the same thing a bit more directly: it was developing senolytic therapies and treating senescent cells themselves as the relevant target. That is a wording shift, not a strategic turn. What stayed stable is the core thesis: cellular senescence matters in aging, and clearing or countering senescent cells could treat age linked disease. The January language is slightly sharper because it names senescent cells explicitly rather than senescence related processes in general. Still, both statements point to the same therapeutic bet. Evidence is thin. We have two website snapshots one month apart, and both are high level company descriptions rather than technical updates, program disclosures, or clinical data. So the safest reading is continuity with minor tightening of language, not a meaningful evolution in belief.